Lv02
0 积分 2023-09-29 加入
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed and refractory multiple myeloma previously treated with lenalidomide
3小时前
已完结
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
3小时前
已完结
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
3小时前
已关闭
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
3小时前
已完结
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
3小时前
已完结
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
4小时前
已完结
Mezigdomide, carfilzomib, and dexamethasone versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma (SUCCESSOR-2): a phase 3, open-label, randomised controlled trial
4小时前
已完结
GD2 ‐ CAR T Cell Therapy for H3K27M + Diffuse Intrinsic Pontine Glioma: A Phase I Clinical Trial and Mechanistic Insights
2个月前
已关闭
Tuberculosis: An Ongoing Global Threat
3个月前
已关闭
皖公网安备34019202002308
